يعرض 1 - 8 نتائج من 8 نتيجة بحث عن '"Ellen C Dompeling"', وقت الاستعلام: 0.38s تنقيح النتائج
  1. 1

    المساهمون: Human Genetics, ARD - Amsterdam Reproduction and Development, Clinical Haematology, AII - Cancer immunology, CCA - Cancer Treatment and Quality of Life, Experimental Immunology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Hematology

    المصدر: The Lancet Haematology, 9(3), e190-e199. Lancet Publishing Group
    The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD

    وصف الملف: application/pdf

  2. 2

    المساهمون: Hematology, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, Human Genetics, ARD - Amsterdam Reproduction and Development

    المصدر: The Lancet Oncology, 23(6), 818-828. Lancet Publishing Group
    Kater, A P, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, van der Kevie-Kersemaekers, A-M F, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Brieghel, C, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Niemann, C U 2022, ' Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION) : primary analysis of an open-label, randomised, phase 2 trial ', The Lancet Oncology, vol. 23, no. 6, pp. 818-828 . https://doi.org/10.1016/S1470-2045(22)00220-0
    Lancet Oncology, 23(6), 818-828. ELSEVIER SCIENCE INC
    The Lancet. Oncology, 23(6), 818-828. Lancet Publishing Group

    وصف الملف: application/pdf

  3. 3

    المساهمون: Hematology, Human Genetics, AII - Cancer immunology, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life

    المصدر: Blood, 137(8), 1117-1120. AMER SOC HEMATOLOGY
    Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608
    Blood, 137(8), 1117-1120. American Society of Hematology
    Niemann, C U, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C H M, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Ranti, J, Mattsson, M, Bellido, M, Tran, H T T, Nasserinejad, K & Kater, A P 2021, ' Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia ', Blood, vol. 137, no. 8, pp. 1117-1120 . https://doi.org/10.1182/blood.2020008608

    وصف الملف: application/pdf; Print

  4. 4

    المصدر: Niemann, C U, Dubois, J, Brieghel, C, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Juha Ranti, J, Mattsson, M, Bellido, M, Nasserinejad, K, Tran, H T T, Levin, M-D & Kater, A P 2021, ' Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD – Primary Analysis from the Randomized Phase II Vision HO141 Trial ', Blood, vol. 138, no. Supplement 1, 69 . https://doi.org/10.1182/blood-2021-148630

  5. 5

    المصدر: Niemann, C U, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Juha Ranti, J, Mattsson, M, Bellido, M, Tran, H T, Nasserinejad, K, Levin, M-D & Kater, A P 2019, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) – 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial ', Blood, vol. 134, no. Supplement 1, 4292 . https://doi.org/10.1182/blood-2019-124377
    Niemann, C U, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, G J, Mous, R, Mellink, C, Dobber, J A, Poulsen, C B, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, E C, Juha Ranti, J, Mattsson, M, Bellido, M, Tran, H T, Nasserinejad, K, Levin, M-D & Kater, A P 2019, ' Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) – 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial ', American Society of Hematology: 61st Annual Meeting (ASH), Orlando, United States, 07/12/2019-10/12/2019 . < https://ashpublications.org/blood/article/134/Supplement_1/4292/425636/Venetoclax-and-Ibrutinib-for-Patients-with >
    University of Southern Denmark

  6. 6
  7. 7
  8. 8